Global Neglected Tropical Diseases Market Overview:
Neglected Tropical Diseases (NTDs) are a category of tropical infections that are prevalent in low-income communities in Africa, Asia, and the Americas. Viruses, bacteria, protozoa, and parasitic worms are among the pathogens that cause them. These diseases are compared with the major three infectious diseases (HIV/AIDS, tuberculosis, and malaria), which are treated and researched more extensively. The combined impact of these diseases in Sub-Saharan Africa is equivalent to malaria and tuberculosis. Neglected tropical diseases impact the poorest members of society in developing nations. The burdens of neglected tropical diseases are frequently overshadowed by other public health problems in countries like these. Many of the same questions, however, put populations of developed and emerging countries at risk. As the research and awareness about these diseases increase, the demand and capacity for their treatment are also increasing.
Growth Drivers
- Huge Amount of Population Which Needs Treatment of Neglected Tropical Diseases
- WHO Campaigns And Funding Driving The Neglected Tropical Diseases Market
Market Trends
- Increasing Donations for The Treatment of Neglected Tropical Diseases
- Growing Awareness About Economic Impact of Neglected Tropical Diseases
Roadblocks
- The inability of Many Nations States to Pay Attention to Neglected Tropical Diseases
Opportunities
- Increasing Number of Policies to Curb Neglected Tropical Diseases
- Growing Quality of Health Infrastructures in Nations Like China and India
Challenges
- Drug and Treatment Delivery to Remote Areas Is Challenging
- As Profit Is Less in The Treatment of Neglected Tropical Diseases There Is Lack of Efforts by Companies
Competitive Landscape:
Some of the key players profiled in the report are F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), GSK (United Kingdom), Novartis AG (Switzerland), Pfizer, Inc. (United States), Eisai Co. Ltd. (Tokyo), Sanofi (France), Astellas Pharma (Japan), Takeda Pharmaceutical Company Limited (Japan) and Gilead Sciences (United States). Considering Market by Therapy, the sub-segment i.e. Drugs will boost the Neglected Tropical Diseases market. Considering Market by Disease, the sub-segment i.e. Buruli Ulcer will boost the Neglected Tropical Diseases market. Considering Market by Age, the sub-segment i.e. Adults will boost the Neglected Tropical Diseases market. Considering Market by Tests, the sub-segment i.e. General Check-up will boost the Neglected Tropical Diseases market.
On 5th April 2018, Takeda Pharmaceutical Co., Ltd. and the Drugs for Neglected Diseases initiative have announced a collaboration to perform preclinically and phase I clinical trials on drug candidate compounds found in the aminopyrazole compound class, with the aim of creating a novel drug for the treatment of visceral leishmaniasis. They will contribute to the advancement of therapies for Neglected Tropical Diseases through this program.
WHO has provided guidelines for the use of ferritin concentrates to access iron status in individuals and populations. These guidelines are regarding the use of Ferritin which is used to tackle iron deficiency in the population. According to guidelines- “Ferritin concentration is a good marker of iron stores and should be used to diagnose iron deficiency in otherwise apparently healthy individuals. In individuals with infection or inflammation, a ferritin concentration below 30 μg/L in children and 70 μg/L in adults may be used to indicate iron deficiency”
What Can be Explored with the Neglected Tropical Diseases Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Neglected Tropical Diseases Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Neglected Tropical Diseases
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Neglected Tropical Diseases market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Neglected Tropical Diseases market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Neglected Tropical Diseases Treatment Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.